Business Context and Reporting Period
Company: Medical Transcription Billing, Corp. (Note: The filing identifies the registrant as Medical Transcription Billing, Corp., not Carecloud, Inc.)
Filing Type: Form 8-K (Current Report)
Date: September 20, 2018
Event: Entry into a Material Definitive Agreement to modify an existing credit facility.
Key Financial Metrics and Transaction Details
- Credit Facility Increase: Revolving line of credit increased from $5,000,000 to $10,000,000.
- Lender: Silicon Valley Bank (SVB).
- Interest Rate: Prime rate plus 1.50% on outstanding balances.
- Fees: 0.5% fee on unused availability; 1% fee payable at closing.
- Equity Component: Issuance of a warrant to SVB for 150,000 shares of common stock (strike price based on trading prices around the issue date).
- Collateral: Secured by substantially all of the Company's assets.
- Use of Proceeds: Growth and general working capital purposes.
Note: This filing does not provide specific revenue, profit, cash flow, or margin figures for the period.
Material Changes Versus Prior Period
The primary material change is the doubling of the Company's available revolving credit line with Silicon Valley Bank. No comparative financial performance data (e.g., year-over-year revenue or earnings) is provided in this specific 8-K filing.
Guidance, Outlook, and Risks
- Outlook: Proceeds are designated for company growth and working capital.
- Risks/Contingencies: The Company's obligations are secured by substantially all assets. The filing includes standard disclaimers that representations and warranties may change and that investors are not third-party beneficiaries of the credit agreement.
- Unusual Items: The transaction includes a warrant issuance as part of the loan modification, which may result in future dilution.
Important Facts for Investor Verification
- Verify the current utilization rate of the new $10,000,000 credit line.
- Confirm the exact strike price of the 150,000 warrants issued to SVB based on the 15-day trading window.
- Review the full text of the Joinder and First Loan Modification Agreement (Exhibit 10.1) for specific covenants and default conditions.
- Assess the impact of the 1% closing fee and ongoing unused availability fees on cash flow.